Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Chellaram Diabetes Research Centre
Eligibility
Inclusion criteria
Inclusion criteria: Subjects from Indian population diagnosed with Type 2 diabetes according to the criteria of the American Diabetes Association. Subjects having with HbA1c in the range of 7.5–12% and either on monotherapy or combination therapy on antidiabetic drugs. Subjects over 18 years old and below 60 years Subjects who agree with the written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Other than Indian ethnicity Under 18 years old Pregnant or lactating women Patients with malignancies, and chronic kidney disease stage 3–5, liver cirrhosis Presently suffering from congestive heart failure requiring pharmacologic treatment (medical history) Past history of urinary or gastric retention or narrow-angle glaucoma Presently severe anaemia Taking a medication that could confound study results, such as known substrates or inhibitors of OCT3 and MATE1, such as cimetidine. They do not provide consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genetic association of response to anti-diabetic drugs with a particular SNP or SNPs Responders and non-responders based on HbA1c % (less than 7% and above 7%) - allele frequency of each SNP Timepoint: 0 month 3 months 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Information on genetic polymorphism and variant allele frequency at the studied loci in the study population will be obtained. Development of a SNP Genotyping assay for pharmacogenomic assessment of T2D patients. Development of matrix for treatment decision based on the pharmacogenomic information. Timepoint: After 6 months | — |
Countries
India
Contacts
Public ContactYashwant Chavan
geneOmbio Technologies Pvt Ltd
Outcome results
None listed